RecruitingMigraine Disorders
MMA Embolization for Refractory Chronic Migraine
Eligible age
18–65 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.
Where it's recruiting
Arizona
Phoenix
California
Walnut Creek
Connecticut
Hartford
New York
Buffalo · New York · Stony Brook
Pennsylvania
Philadelphia
Tennessee
Memphis
West Virginia
Morgantown
Source: ClinicalTrials.gov · NCT06735833 · last updated 2026-06-08